Carlyle Group has entered an agreement, through which its affiliate Murano Bidco will acquire 100% shares of pharmaceutical firm Vectura Group in a deal worth $1.36bn (£958m).

According to the deal, Vectura shareholders will receive $2 (£1.55) for each share, including a cash dividend of $0.27 (£0.19). The total acquisition value represents a premium of nearly 27% of the closing price of $1.7 (£1.22) per share of Vectura on 25 May.

Murano Bidco is a recently founded company that is indirectly controlled by Carlyle Europe Partners V Fund.

A UK-based pharmaceutical company, Vectura focuses on providing inhaled drug delivery solutions that aid its partners to deliver their treatments to patients.

The company has a portfolio of 13 inhaled and 11 non-inhaled products that are commercialised by its partners with royalty streams globally.

It also has a partnered portfolio of therapies that are currently in the clinical developmental stage.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Vectura is collaborating with various companies including Hikma, Novartis, Sandoz, Mundipharma, Kyorin, GlaxoSmithKline (GSK), Bayer, Chiesi, Almirall and Tianjin KingYork.

Vectura Group chairman Bruno Angelici said: “Vectura has made strong progress since embarking on its new strategy in 2019 to become a leading inhalation-focused CDMO whilst continuing to deliver strong financial and operational results in its royalties and product supply businesses.

“While the Vectura directors remain confident in the long-term fundamentals of the Vectura Group, we believe that this is an attractive offer for Vectura shareholders, which secures the delivery of future value for Vectura shareholders in cash today.”

With the acquisition, Bidco expects that Vectura could better attain its complete potential in a private setting through increased growth investments.

Furthermore, Carlyle could utilise Vectura’s network globally, along with resources and expertise to aid in reaching this potential.

JP Morgan Cazenove and Rothschild served as advisors to Vectura on the financial terms of the deal.

Subject to necessary terms and conditions, the deal is anticipated to conclude in the third quarter of this year.